Sara Barulli
Pesaro, 61121, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact (D-IMPACT) Project.
Journal: Cancers
Published: April 08, 2026
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
Journal: British journal of haematology
Published: July 11, 2021
Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib.
Journal: Frontiers in oncology
Published: February 25, 2021
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.
Journal: Blood advances
Published: August 20, 2019
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine.
Journal: The pharmacogenomics journal
Published: December 04, 2016
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories.
Journal: Oncotarget
Published: November 01, 2016
Advancement in high dose therapy and autologous stem cell rescue in lymphoma.
Journal: World journal of stem cells
Published: November 25, 2014
Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.
Journal: American journal of hematology
Published: September 11, 2013
High-dose therapy followed by stem cell transplantation in Hodgkin's lymphoma: past and future.
Journal: Expert review of hematology
Published: September 03, 2013
Third party cord blood transplant boosts autologous hematopoiesis in a case of persistent bone marrow aplasia after double transplant failure for B-thalassemia major.
Journal: Mediterranean journal of hematology and infectious diseases
Published: January 24, 2013
Autologous stem cell transplantation for aggressive lymphomas.
Journal: Mediterranean journal of hematology and infectious diseases
Published: October 22, 2012
Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia.
Journal: Acta haematologica
Published: April 18, 2012
Showing 1-12 of 12
Last Updated: 09/26/2026